$CURR got an impressive $20 million for selling just one of their IP assets and that major cash infusion has been put to very good use. The company still has 15 more patents in its inventory and plenty of options to continue growing its revenues from the sales of the very successful Sera Labs beauty and wellness product lines.

From CURR management:

As we have previously reported, other important company developments already include strong sales results and revenue growth. Plus, we completed sale of a portion of our platform technology intellectual property portfolio and related assets in July 2022 for $20 million of non-dilutive capital in total consideration. A portion of the cash proceeds was used to pay down certain debt obligations and the balance is being used for working capital and to grow the Company's intellectual property portfolio and its wellness and beauty brands. The Company retained 15 of its patents and will continue to be an incubator for future technologies and patents, which it intends to monetize through the commercialization of the technologies through product development or through the licensing/sale of the technologies.

News Link:
https://www.accesswire.com/731950/CURE-Pharma...areholders